Profile data is unavailable for this security.
About the company
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
- Revenue in CNY (TTM)23.68bn
- Net income in CNY-6.52bn
- Incorporated2010
- Employees10.47k
- LocationBeigene LtdC/O Mourant Governance Services (Cayman)94 Solaris Avenue, Camana BayGRAND CAYMAN KY1-1108Cayman IslandsCYM
- Phone+1 3 459494123
- Websitehttps://www.beigene.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WuXi AppTec Co Ltd | 38.50bn | 8.06bn | 148.09bn | 41.12k | 18.95 | 2.75 | -- | 3.85 | 2.75 | 2.75 | 13.12 | 18.95 | 0.5274 | 4.35 | 4.27 | 936,411.20 | 11.17 | 11.76 | 14.15 | 15.00 | 39.83 | 38.46 | 21.18 | 21.69 | 1.94 | 18.51 | 0.1131 | 30.01 | 2.51 | 33.22 | 9.00 | 33.56 | 19.66 | 32.04 |
| Beigene Ltd | 23.68bn | -6.52bn | 157.27bn | 10.47k | -- | 9.71 | -- | 6.64 | -4.82 | -4.82 | 17.46 | 17.44 | 0.5845 | 1.50 | 7.62 | 2,261,431.00 | -16.10 | -27.60 | -22.73 | -35.00 | 83.13 | 83.23 | -27.55 | -122.16 | 1.72 | -- | 0.2594 | -- | 82.13 | 67.79 | 50.77 | -- | 41.60 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 6.74m | 5.86% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2024 | 3.61m | 3.13% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 2.91m | 2.53% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2024 | 2.29m | 1.99% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 1.82m | 1.58% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 1.41m | 1.22% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 1.40m | 1.22% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2024 | 1.34m | 1.16% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2024 | 1.31m | 1.14% |
| China Fund Management Co., Ltd.as of 30 Jun 2024 | 1.20m | 1.04% |
